Quick Answer
Galera Therapeutics, Inc. reported Operating Income of -$2.54 million for fiscal year 2025.
Galera Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$2.54M | +87.4% |
| 2024 | -$20.16M | +59.1% |
| 2023 | -$49.26M | +3.8% |
| 2022 | -$51.23M | +30.2% |
| 2021 | -$73.37M | -4.0% |
| 2020 | -$70.55M | -39.2% |
| 2019 | -$50.69M | -109.0% |
| 2018 | -$24.25M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.44M | +75.7% | -26.5% |
| June 30, 2025 | -$1.14M | +73.0% | +42.2% |
| March 31, 2025 | -$1.96M | +57.1% | +66.8% |
| September 30, 2024 | -$5.91M | +55.9% | -40.4% |
| June 30, 2024 | -$4.21M | +75.0% | +8.0% |
| March 31, 2024 | -$4.58M | +67.0% | +65.8% |
| September 30, 2023 | -$13.40M | -3.4% | +20.3% |
| June 30, 2023 | -$16.81M | -40.9% | -21.1% |
- Galera Therapeutics, Inc. showed an increase of +87.4% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Galera Therapeutics, Inc.’s operating income has grown by 89.5% (from -$24.25 million to -$2.54 million).
- The most recent figure is from Galera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: